Stablecoin Development Earnings Call Transcripts
Fiscal Year 2026
-
Six proposals were presented and approved, including major share issuances, amendments to the certificate of incorporation, and a new equity incentive plan. Quorum was established with over 96% voting power represented, and the meeting concluded with a Q&A session.
Fiscal Year 2024
-
The meeting focused on two major proposals: selling Avenova and dissolving the company. Due to insufficient votes, both proposals were adjourned for further solicitation, with the meeting set to reconvene on January 16th, 2025.
-
Eye care sales grew 8% year-over-year in Q2 2024, with gross margin rising to 66% due to a higher-margin product mix. Subscription sales now account for 24% of online revenue, and a recent capital raise strengthens the balance sheet for strategic initiatives.
Fiscal Year 2023
-
Q2 revenue rose 26% to $4.6M, with record wound care sales and a 37% narrower operating loss. Management expects incremental eye care growth, focuses DERMAdoctor on profitable core products, and anticipates ~55% second-half gross margin.